6. PART VI – SUMMARY OF THE RMP

6.1 Overview of disease epidemiology

6.1.1 Pain

Pain is a common complaint among adults, with almost one-fifth reporting general pain, one-third shoulder pain, and up to one-half reporting lower back pain.² Acute pain (pain starting suddenly and for shorter duration of time) is the most common symptom for which patients seek medical care. More than half of cases of long standing pain is related to pain of muscles, bones and joints.³ Approximately, 10% of the general population in the Western suffers from chronic pain of muscles, bones and joints, and is frequent among women as compared with men.⁴

6.1.2 Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic condition which causes pain and swelling of the joints. RA patients may lead to increased risk of death, and the expected duration of life of RA patients is likely to decrease by 3-10 years. In North America and Northern Europe, 0.5-1.1% of the population is diagnosed with RA.⁵ The main risk factors for the disease include genetic factors, sex, age, smoking, infectious agents, hormonal, dietary, socioeconomic (social standing measured as a combination of education, income and occupation) and ethnic factors.⁶

6.1.3 Dysmenorrhoea

Most women experience some form of pain during their periods and it affects up to 80% of women in their child bearing age. The risk factors include age at which first menstrual cycle starts, body weight, dietary habits, associated menstrual disorders, diseases of the uterus, and psychosocial problems.⁷ Pain during periods in female teenagers usually has no cause and is associated with normal menstrual cycles; only in 10% of teenagers with severe pain during periods, pelvic diseases may be found.⁸

6.2 Summary of existing efficacy data

6.2.1 Pain

Ibuprofen was the first approved pain killer to be sold without doctor's prescription.⁹ Ibuprofen in lower doses (200-400 mg/day) is as effective as aspirin in moderate pain but superior to aspirin or paracetamol in pain of teeth.¹⁰ Higher doses (1,800-2,400 mg/day) are used in more severe conditions involving muscles, bones and joints.¹¹ Ibuprofen is as or more effective than paracetamol for the treatment of pain and fever in adult and children populations.¹²

6.2.2 Rheumatoid arthritis

In higher doses (1,200-2400 mg/day), ibuprofen is as effective as aspirin, piroxicam and other pain killers in the treatment of pain associated with swelling, stiffness, and redness in the joints.¹³⁻¹⁵ Studies conducted in RA patients showed that pain killers: naproxen, **ibuprofen**,



fenoprofen, tolmetin, diclofenac, mefenamic acid, ketoprofen, and indomethacin are equally effective.¹⁶⁻²⁰

6.2.3 Dysmenorrhoea

In a study, placebo and paracetamol were compared to ibuprofen in patients suffering with pain during periods. The results showed that both ibuprofen and paracetamol were superior to placebo in providing relief from pain.²¹ In a systematic review of pain killers ibuprofen appeared to be the most favourable pain killer because of fewer side effects as compared to other pain killers (naproxen, mefenamic acid and aspirin).²² In an another study of young women with severe and disabling pain of periods, ibuprofen was shown to be effective in relieving the pain.²³ Also, ibuprofen and ketoprofen (medicine similar to ibuprofen) were found to be equally effective in a study for relief of pain during periods.²⁴

6.3 Summary of safety concerns

The common side effects are related to digestive system which include indigestion, diarrhea, stomach and / bowel bleeding (vomiting of blood, and black colored stools due to blood in stools), abdominal pain, flatulence, nausea, vomiting, constipation, cramps in stomach. There may be open sores in the lining of stomach and / or bowel and bleeding from stomach or bowel, which can be fatal, especially in the elderly. The other common side effects include mild and transient headache, dizziness, ringing in the ears, and increased urea concentration in blood, increased blood creatinine levels, rashes, and weakness. A full list of all side effects reported with ibuprofen is presented in the SmPC and the package leaflet.

The following table provides information on the important identified risks and their preventability:

Risk	What is Known	Preventability
Effects on digestive system (Gastrointestinal effects)	Ibuprofen can cause bleeding, ulcers or holes (perforations) in the stomach and intestines that can lead to death. The chances of bleeding or perforations are higher:	Ibuprofen should not be taken in patients who have ulcers and bleeding from the stomach or bowel.
	 With increasing doses of painkillers (NSAIDs) (Ibuprofen is a type of NSAID) In patients with a history of ulcers, especially when there is bleeding or perforation and in the elderly patients) 	Ibuprofen should also not be taken by patients who have ulcerative colitis (a disease of the large intestine), Crohn's disease, or ulcers in the stomach or bleeding more than once.
		Patients should stop taking ibuprofen and contact their doctors if they experience pain in the upper part of the



		stomach and/or bleeding from the stomach or bowel while taking ibuprofen. The patients should also inform their doctors if they have or have had ulcerative colitis or Crohn's disease.
Effects on heart and brain (Cardiovascular and cerebrovascular effects)	Increased blood pressure and fluid retention in the body have been reported in association with NSAID therapy. Use of ibuprofen might be associated with a slightly higher risk of heart attack and stroke (condition that occurs when the blood supply to part of the brain is cut off). The risk is increased when ibuprofen is used for prolonged periods or used at higher doses.	Ibuprofen should not be taken by patients with severe heart failure. The patient should consult doctor if he/she has heart problems, previous history of stroke or are at high risk for this (for e.g. if he/she has high blood pressure, diabetes, high cholesterol or is a smoker). The recommended dose for treatment should not normally be exceeded.
Effects on kidney (Renal effects)	 Use of NSAIDs may result in deterioration of kidney function. Those with greatest risk are: Impaired kidney function patients Heart failure patients Impaired liver function patients Patients treated with water pills (diuretics) Patients treated with blood pressure lowering medication (angiotensin converting enzyme inhibitors) Elderly patients Long term treatment with ibuprofen results in pathological changes in the 	The patient should inform his doctor about heart problems or kidney problems or about concomitant use of medicines such as water pills or blood pressure lowering drugs. Ibuprofen should not be taken by patients with severe kidney impairment.
Liver impairment (Hepatic impairment)	kidney. Ibuprofen should be used with caution in patients with impaired liver function, because liver toxicity can occur.	Ibuprofen should not be used in patients with severe liver impairment
Increased bleeding (Bleeding disorder)	Ibuprofen like other NSAIDs, prevent blood clotting and has been shown to prolong bleeding time in normal individuals.	Ibuprofen should not be used in patients with severe reduction in platelet counts or who are taking blood thinning



		agents.
Skin effects	Serious skin reactions, some of them	The patient should stop the
	leading to death have been reported	treatment and contact his
	very rarely in association with the use	doctor immediately if he or
	of NSAIDs. The risk of such reactions	she develops a rash, bleeding
	appears to be highest early in the	from mucous membranes or
	treatment. The patient should stop the	other allergic reactions.
	treatment and contact his doctor	
	immediately if he or she develops a	
	rash, bleeding from linings of stomach	
	or bowel or other allergic reactions	
Use in asthmatic and	Ibuprofen can cause bronchospasm in	Ibuprofen should not be given
aspirin or other	asthmatic patients (condition that can	to patients with history of any
NSAID sensitive	cause a cough, wheezing and	allergy to aspirin or other
patients	breathlessness)	NSAIDs.
Concomitant use with	Co-administration of ibuprofen with	The patient should inform his
other NSAIDs	other NSAIDs, especially aspirin	doctor before starting the
	increases the risk of side effects. In	treatment with ibuprofen, if
	addition, ibuprofen inhibits the blood	aspirin is concomitantly used.
	thinning effect of low dose aspirin.	

The following table provides important missing information with the drug product:

Important Missing	What is Known
Information	
Use during pregnancy, lactation and in women who want to conceive (Use in pregnancy / lactation and in women during age of fertility, wishing to become pregnant)	Ibuprofen, if administered to pregnant women during the last three months of pregnancy may expose foetus to heart and lung toxicity and kidney dysfunction. Ibuprofen should not be given to women during the last three months of pregnancy. In the first 6 months of pregnancy, it should be used only if clearly needed and the dose should be kept as low and duration of treatment as short as possible.
	Ibuprofen can be used during lactation. However, there should be risk/benefit assessment because infants and children are particularly sensitive to ibuprofen effect.
	The use of ibuprofen may reduce fertility and therefore should not be used in women who want to conceive. For women who have trouble conceiving or are undergoing investigation of infertility, withdrawal of ibuprofen should be considered. Ibuprofen should not be used in women who want to become pregnant as it can reduce fertility. If treatment with ibuprofen is required, it should be short and with lowest dose possible.
Use in children < 15 years	Children are particularly sensitive to ibuprofen effect. Hence ibuprofen should not be used in children less than 15 years.



Risk Management Plan	Alternova A/S Ibupama 400 mg & 600 mg tablets
Long term use	Long-term treatment with ibuprofen may result in worsening of the pre-existing headache or more frequent attacks of headaches. If this condition develops or is suspected, the patient should seek medical attention for stopping the treatment.

6.4 Summary of risk minimisation activities by safety concern

Routine risk minimisation is provided through the <u>SmPC</u> and the <u>Patient Information Leaflet</u>. The SmPC of Ibupama tablets is consistent with that of the reference medicinal product.

Routine pharmacovigilance activities are sufficient to identify the actual and potential risks of ibuprofen and no additional post authorization safety studies or risk minimization measures are required.

6.5 Summary of changes to the risk management plan over time

This is the first risk management plan for Ibupama 400 / 600 mg film coated tablets.